durga ganesh 2011

8/7/2019 durga ganesh 2011

1/31

welcome


2/31

Symbol&tagline


3/31

history

Kallam Anji Reddy (born 1940) is an Indian entrepreneur inthe pharmaceutical industry,

the founder-chairman ofDr Reddy's Labs, which he established in

1984,

chairman of Dr Reddys Foundation (DRF), the corporate social

responsibility arm of the group, established 1996.[1][2]


4/31

Kallam Anji Reddy

Born 1940

Tadepalli, Guntur district

Nationality Indian

Occupation Chairman, Dr Reddy's Labs


5/31

Early life and education

He spent his early years in the village ofTadepalli nearGunturin Guntur

District, where his father grew turmeric.

Reddy graduated from the local high school and went on to get his first

Bachelor of science degree fromA.C. College at Gunturin 1958.[3]

Thereafter he, did his B.Sc.-Tech in Pharmaceuticals and Fine chemicals

from Bombay University followed by a Ph.D. in chemical engineering from

the National Chemical Laboratory, Pune in 1969.[4]


6/31

Social causes

Naandi Foundation, a not-for-profit development institution that

strives for eradication of poverty has Dr Reddy as its founding

father.

He is also founder-chairman of Dr Reddys Foundation forHumanand Social Development, a social arm of Dr. Reddys Labs


7/31

Principal Competitors: RPG Enterprises; GlaxoSmithKline

ConsumerH

ealthcare Ltd.;

East India Pharmaceutical Works Ltd.; Cipla Ltd.;

Concept Pharmaceuticals Ltd.

;

Khandelwal Laboratories Ltd.

;

Dabur India Ltd.


8/31

Vision and Mission

by Global Report Initiative G3, covering social, ethical,

economic, nvironmental aspects of our business.

At Dr. Reddys, sustainability is a multi-dimensional

aspiration.

which has its roots in the very purpose of our existence

providing affordable medicines to people around the world

and meeting unmet medical needs through innovation.


9/31

Objectives

Discuss with senior management, the Companys Enterprise Risk

Management.

and provide oversight as may be needed;

- Ensure it is apprised of the most significant risks along with the

action management is

taking and how it is ensuring effective ERM;

- Reviewing risk disclosure statements in any public documents or

disclosures.


10/31

Role of Board of directors

Dr. Reddys Board of Directors

comprises eminent individuals from

diverse fields

Directors are experts in the diverse

fields of medicine,

And chemistry and medical research

human resource development,

business strategy, finance, and

economicsDr. K.anjireddy

chairman


11/31

Top products

Nise

Omez Stamlo

Stamlo beta

Atocor

Omez_z Razo

Enam


12/31

Shareholding Pattern on March 31, 2011

PROMOTERS HOLDING:No. of

Shares% of Shares

Individuals 4,289,484 2.53

Companies 39,128,328 23.12

Sub Total 43,417,812 25.65

Indian Financial

Institutions13,863,468 8.19

Banks 400,722 0.24

Mutual Funds 9,451,142 5.58

Sub Total 23,715,332 14.01


13/31


14/31

Head Quarters & branches

Rest of the World India

North America

Russia and CIS

Europe Source: Evalueserve

7-1-27, AmeerpetHyderabad, 500 016

India


15/31

Mile Stones

Announces strategic alliance with GlaxoSmithKline plc to develop.

and market select products across emerging markets outside India

.

Receives approval for Three INDs.

Reorganizes Drug Discovery Operations to merge into Aurigene, a wholly

owned independent subsidiary of Dr. Reddy's


16/31

Head Quaters

7-1-27, Ameerpet

Hyderabad, 500 016

India


17/31

Employees Motivation

the company attaches great importance to

provide a work culture that allows.

employees the freedom to learn, innovate,

experiment and grow.

An attractive compensation and benefits

plan can look even better Performance

management process flows from an in-

house variant of the balanced

Dr. Reddy's also fosters a sense of

belonging


18/31

Reddy labs organization structer

Name Age Since Current Position

Reddy, K. Anji 72 Chairman of the Board

Prasad, G. 50 Vice Chairman of the

Board, Chief Executive

Officer

Vohra, Umang 39 Chief Financial Officer

Mukherjee, Abhijit 52 2010 President - Global

Generics

Chakraborty, Saumen 49 2009 President - Corporate

Reddy, Satish 43 Chief Operating Officer,

Managing Director,

Director


19/31

Reddy, Satish 43 Chief Operating Officer,

ManagingDirector, Director

Rao, K. B. Sankara 56 2006 Executive Vice President -

Integrated Product

Development Business

Dholye, Vilas 61 Executive Vice President -

Formulations Manufacturing

Jha, Prabir 43 2007 Senior Vice President, Global

Chief of Human Resources

Patel, Amit 36 2008 Senior Vice President -

North America Generics

business


20/31


21/31

AWARDS

Dr. Reddy's receives The award for 'Business Leader in the

Pharmaceutical Sector

at the NDTVProfit Business Leadership Awards 2010

MD and COO, SATISH REDDY, received the award from Union

Finance Minister Mr. PRANAB MUKHERJEE on the company'sbehalf.


22/31


23/31

4. Making the board an ally. Developments such as Sarbanes-Oxley and the

global financial crisis have further distilled corporate boards into the role of

scrutinizing and interrogating management.


24/31

campus recruitment

We recruit from premier Business and Technical schools

.

We look for those who dare to dream. Love ambiguity and challenge.

.

programs like Global Internship, your 8 weeks of live project with us

could help you discover where you really want to be at Dr. Reddys.


25/31

Recruitment process

Company recruits the people form campus interviews

Return test

interviews


26/31

Major Achievements of Dr. Reddy's Laboratories

Dr. Reddy's is the 1st Asia Pacific pharmaceutical company,

outside Japan to be listed on the New York Stock Exchange.

Dr. Reddy's biologics product Reditux (Rituximab) is the firstbiosimilar monoclonal antibody to be developed and launched

anywhere in the world.


27/31

Balance sheet

Assets

Current Assets

Cash And Cash Equivalents 7,730,000 5,596,000 186,278

Short Term Investments 3,600,000 530,000 119,315

Net Receivables 12,490,000 14,650,000 187,839

Inventory 13,371,000 13,226,000 279,434

Other Current Assets 5,445,000 5,008,000 96,101

Total Current Assets 42,063,000 39,010,000 868,967


28/31

liabilities

Current Liabilities

Accounts Payable 10,754,000 6,619,000 240,503

Short/Current LongTerm Debt

9,271,000 9,683,000 167,606

Other CurrentLiabilities

8,997,000 10,251,000 78,637

Total Current Liabilities 29,022,000 26,553,000 486,746


29/31

Top active pharmaceutical ingredients

Ciprofloxacin Hydrochloride

Ramipril Terbinafine HCI

Ibuprofen

Sertaline Hydrochloride

Ranitidine HCI Form 2


30/31


31/31

Documents

durga ganesh 2011